VRTX
Vertex Pharmaceuticals
NASDAQ: VRTX · Boston, MA · Healthcare
$445.77+2.81 (+0.63%)Closed
Market Cap$112.00B
Cash$13.80Bmost recent
Runwayprofitable
P/E (TTM)29.5EPS $14.72
52-Wk Range$366.54 – $499.17
Avg Volume1.5M3-month
Healthstrong
Commercial-stage biotech with a dominant cystic fibrosis franchise, expanding into pain, T1D, and sickle cell via Casgevy.
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$445.77-7.8%
Pipeline
Drug candidates sponsored by Vertex Pharmaceuticals · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | LUM/IVA | Cystic Fibrosis | Completed | 2020-10-09past | 3 | |
| Phase 3 | Pegylated Interferon Alfa 2a | Hepatitis C | Completed | 2010-05past | 1 | |
| Phase 3 | Telaprevir | Hepatitis C, Chronic+1 more | Completed | 2014-02past | 4 | |
| Phase 3 | Lumacaftor Plus Ivacaftor Combination | Cystic Fibrosis, Homozygous for the F508del CFTR Mutation+1 more | Completed | 2016-04past | 2 | |
| Phase 3 | VX-661 plus ivacaftor combination | Cystic Fibrosis | Completed | 2016-06-07past | 1 | |
| Phase 3 | VX-809 | Cystic Fibrosis | Completed | 2016-09past | 1 | |
| Phase 3 | Lumacaftor | Cystic Fibrosis+1 more | Completed | 2016-10past | 4 | |
| Phase 3 | TEZ | Cystic Fibrosis | Completed | 2018-09past | 1 | |
| Phase 2 | VX-210 | Cervical Spinal Cord Injury | Terminated | 2018-11past | 1 | |
| Phase 3 | TEZ/IVA | Cystic Fibrosis | Completed | 2018-12-21past | 1 | |
| Phase 3 | VX-659/TEZ/IVA | Cystic Fibrosis | Completed | 2019-02-05past | 2 | |
| Phase 3 | Ivacaftor | Cystic Fibrosis | Completed | 2020-10past | 8 | |
| Phase 3 | IVA | Cystic Fibrosis | Completed | 2023-10-02past | 1 | |
| Phase 3 | Biological/Vaccine | Type 1 Diabetes+1 more | Recruiting | 2026-09-17 | 1 | |
| Phase 3 | VX-121/TEZ/D-IVA | Cystic Fibrosis | Active, not recruiting | 2026-10-30 | 3 | |
| Phase 3 | Suzetrigine | Diabetic Peripheral Neuropathic Pain+2 more | Recruiting | 2027-02-26 | 4 | |
| Phase 3 | ELX/TEZ/IVA | Cystic Fibrosis | Active, not recruiting | 2027-04-06 | 11 | |
| Phase 3 | CTX001 | Beta-Thalassemia+6 more | Recruiting | 2027-06-09 | 3 | |
| Phase 3 | VNZ/TEZ/D-IVA | Cystic Fibrosis | Enrolling | 2029-07-30 | 1 | |
| Phase 2 | biricodar dicitrate | Lung Cancer | Terminated | 2001-02past | 1 | |
| Phase 2 | Ivacaftor 25 mg/75 mg | Cystic Fibrosis | Completed | 2008-08past | 1 | |
| Phase 2 | VX-765 | Partial Epilepsy+1 more | Completed | 2010-11past | 2 | |
| Phase 2 | VX-787 | Influenza Virus | Completed | 2012-10past | 1 | |
| Phase 2 | VX-222 | Chronic Hepatitis C Virus | Completed | 2013-06past | 1 | |
| Phase 2 | VX-765 Part A | Epilepsy | Terminated | 2013-08past | 1 | |
| Phase 2 | VX-509 | Rheumatoid Arthritis+1 more | Completed | 2014-01past | 2 | |
| Phase 2 | VX-135 | Chronic Hepatitis C+3 more | Completed | 2014-05past | 1 | |
| Phase 2 | Tezacaftor/Ivacaftor | Cystic Fibrosis | Completed | 2017-06past | 2 | |
| Phase 2 | VX-561 | Cystic Fibrosis | Terminated | 2017-08past | 1 | |
| Phase 2 | VX-152 | Cystic Fibrosis | Completed | 2018-01past | 1 | |
| Phase 1 | Placebo (matched to VX-121 suspension) | Cystic Fibrosis | Completed | 2019-05-03past | 1 | |
| Phase 2 | VX-121 | Cystic Fibrosis | Completed | 2019-12-10past | 1 | |
| Phase 2 | VX-864 | Alpha1-Antitrypsin Deficiency+1 more | Completed | 2024-08-19past | 2 | |
| Phase 2 | VX-150 | Osteoarthritis+3 more | Completed | 2025-03-22past | 4 | |
| Phase 2 | VX-407 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Recruiting | 2027-07-22 | 1 | |
| Phase 2 | Povetacicept | Myasthenia Gravis, Generalized+1 more | Recruiting | 2029-03-02 | 2 | |
| Phase 2 | VX-950 | Hepatitis C | Completed | — | 1 | |
| Phase 1 | telaprevir (VX-950) | Hepatic Insufficiency | Completed | 2008-06past | 1 | |
| Phase 1 | VX-770 | Cystic Fibrosis+1 more | Completed | 2010-12past | 2 | |
| Phase 1 | lumacaftor 200 mg q12h + ivacaftor 250 mg q12h | Hepatic Impairment+1 more | Completed | 2013-11past | 1 | |
| Phase 1 | VX-840 | APOL1-mediated Kidney Disease | Completed | 2022-11-07past | 1 | |
| Phase 1 | VX-708 | Acute Pain | Completed | 2023-04-14past | 1 | |
| Phase 1 | VX-147 | Focal Segmental Glomerulosclerosis (FSGS) | Completed | 2023-09-02past | 1 | |
| Phase 1 | VX-668 | Alpha-1 Antitrypsin Deficiency | Completed | 2023-09-12past | 1 | |
| Phase 1 | VX-548 | Pain | Completed | 2024-03-30past | 4 | |
| Phase 1 | VX-973 | Pain | Completed | 2024-04-04past | 1 | |
| Phase 1 | VX-118 | Cystic Fibrosis | Completed | 2024-05-04past | 1 | |
| Phase 1 | VX-993 | Pain | Completed | 2024-09-10past | 3 | |
| Phase 1 | VX-828 | Cystic Fibrosis | Completed | 2025-05-05past | 1 | |
| Phase 1 | VX-581 | Cystic Fibrosis | Recruiting | 2026-11-19 | 1 | |
| Phase 1 | AVN-944 capsules for oral administration | Acute Leukemia+5 more | Completed | — | 1 | |
| N/A | Unnamed | Cystic Fibrosis | Completed | 2019-12past | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.